Heart failure & cardiomyopathiesSecondary analysis
Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure
- Secondary analysis of the RAFT randomised trial
- long-term follow-up
- 8 highest-enrolling sites
Authors' conclusion
Among patients with a reduced ejection fraction, a widened QRS complex, and NYHA class II or III heart failure, the survival benefit associated with receipt of a CRT-D as compared with ICD appeared to be sustained during a median of nearly 14 years of follow-up.
Study context
- Population
- Patients with New York Heart Association (NYHA) class II or III HF, LVEF ≤30% and intrinsic QRS ≥120 msec (or paced QRS ≥200 msec)of 1798 enrolled
- Participants
- 1,050 patients
- Comparison
- CRT defibrillator (CRT-D) vs ICD alone
- CRT-Dn = 520
- ICDn = 530reference
- Primary endpoint
- Death from any cause
- Follow-up
- Median 7.7 years (IQR 3.9 to 12.8)
Primary result
As reported in the abstract
Acceleration factor
0.80
95% CI 0.69–0.92
P = 0.002
Events by treatment group
Secondary outcomes
Death from any cause, heart transplantation or ventricular assist device implantation
Original publication
Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure. N Engl J Med. Published 18 January 2024. doi:10.1056/nejmoa2304542
Summarised from the published abstract; every number is checked against it